First quarter results
Glenmark Pharmaceuticals reported an 86.2% year-on-year (YoY) decline in net profit at ₹46.8 crore for the first quarter that ended June 30, 2025, down from ₹340.2 crore in Q1FY25. However, revenue increased slightly, up 0.6% at ₹3,264 crore against ₹3,244 crore in the same quarter last year.
Also Read: Glenmark Pharma announces India launch of blood cancer treatment Brukinsa
At the operating level, EBITDA dipped 1.4% to ₹580 crore in this quarter compared to ₹588.2 crore YoY. The EBITDA margin was lower at 17.7% versus 18.1% in the April-July quarter of the previous fiscal.
In India, sales from Glenmark Pharmaceuticals’ formulation business in the first quarter of FY26 stood at ₹1,239.9 crore, compared with ₹1,196.2 crore a year ago, reflecting a 3.7% YoY growth.
In North America, the business registered revenue of ₹778 crore for this quarter, compared with ₹714.6 crore in the fourth quarter of FY25, marking an 8.9% quarter-on-quarter (QoQ) increase. The growth was driven by share gains in injectable product launches and partnered products.
Also Read: Glenmark Pharma’s innovation arm signs exclusive licensing agreement with AbbVie for ISB 2001
Revenue from emerging markets, including RCIS, LATAM, MEA, and APAC, was ₹572.1 crore in the first quarter of FY26, compared with ₹570.8 crore in the year-ago period, registering a 0.2% YoY rise. The company continues to anticipate double-digit growth on a constant currency basis.
Shares of Glenmark Pharmaceuticals Ltd ended at ₹2,014.35, down by ₹70.25 or 3.37%, on the BSE today, September 22.
